SCHEDULE: Matthew Angel Boosts Tempest Therapeutics Stake to 37.4%

Matthew Angel, CEO of Tempest Therapeutics, significantly increased his beneficial ownership to 37.4% through recent asset and securities purchase agreements.

Summary

• Matthew Angel, President and CEO of Tempest Therapeutics, Inc., now beneficially owns 5,531,516 shares of common stock, representing 37.4% of the company's outstanding shares.
• This increased ownership stems from two primary transactions: an asset purchase and a securities purchase.
• On February 3, 2026, Angel acquired 4,837,070 shares indirectly through an Asset Purchase Agreement dated November 19, 2025, where Tempest acquired assets from Erigen LLC and Factor Bioscience Inc. in exchange for 8,268,495 shares issued to Erigen, which were then distributed to its equityholders.
• On March 24, 2026, Factor Bioscience Inc., where Angel is the majority stockholder and Chairman, acquired an additional 231,482 shares of common stock and warrants to purchase 462,964 shares for $500,001.12 through a Securities Purchase Agreement dated March 20, 2026.
• The company has committed to filing registration statements for the resale of shares issued in these transactions and underlying warrants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the substantial increase in insider ownership by the CEO, signaling strong confidence and alignment of interests, coupled with strategic asset acquisition and capital infusion.

Positives

• Significant increase in insider ownership by the CEO, Matthew Angel, to 37.4%, indicating strong confidence in the company's future.
• Strategic acquisition of assets from Erigen LLC and Factor Bioscience Inc. via the Asset Purchase Agreement.
• Successful private placement raising capital (Factor's part was $500,001.12, total private placement involved other institutional investors).

Risks

• The Issuer's agreement to seek stockholder approval for the issuance of shares upon exercise of warrants within 90 days implies a potential risk if approval is not obtained.
• Potential dilution risk for existing shareholders from the issuance of new shares and the future exercise of warrants.

Future Outlook

The Issuer has committed to filing registration statements for the resale of shares issued in the asset purchase and private placement, and for shares underlying warrants, aiming for prompt effectiveness. The company also agreed to seek stockholder approval for the issuance of shares upon warrant exercise within 90 days.

Management Comments

• Mr. Angel is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
• The Reporting Person used personal funds to acquire a membership interest in Erigen and securities in Factor, and ultimately the shares of the Issuer.

Industry Context

StockSavvy.ai notes that significant insider ownership, especially by a CEO, can be a strong signal of confidence in a company's long-term prospects, particularly in the biotechnology sector where development timelines are long and capital requirements are high. The strategic acquisition of assets and a concurrent private placement suggest a focus on expanding the company's pipeline or capabilities.

Comparison to Industry Standards

• Insider ownership of 37.4% by a CEO is substantially higher than the average for publicly traded biotech companies, which typically ranges from 5-15% for founders/executives post-IPO. This level of ownership aligns more with a founder-led private company transitioning to public, or a company undergoing a significant strategic shift.
• The use of shares as consideration for asset purchases is common in early-stage biotech, conserving cash.
• The private placement structure with warrants is a standard financing mechanism for growth-stage biotech firms, often used to bring in institutional investors and provide additional capital upon warrant exercise.

Management Changes

Corporate Governance

Related Party Transactions

• Matthew Angel, as the Reporting Person, is the President and CEO of Tempest Therapeutics.
• Matthew Angel is also the majority stockholder and Chairman of the Board of Directors of Factor Bioscience Inc., which was a seller in the Asset Purchase Agreement and an investor in the Securities Purchase Agreement.
• The Asset Purchase Agreement involved Erigen LLC and Factor Bioscience Inc. as sellers, with shares issued to Erigen and subsequently distributed to its equityholders, including Matthew Angel.
• The Securities Purchase Agreement involved Factor Bioscience Inc. as one of the investors.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrant exercises, but also increased insider confidence and strategic asset acquisition. The lock-up agreement provides some stability for a portion of the newly issued shares.
• Management: Matthew Angel's role as CEO and significant shareholder aligns his interests directly with the company's performance.
• Investors (in private placement): Gained shares and warrants, with registration rights to facilitate future liquidity.

Next Steps

• Issuer to prepare and file a registration statement on Form S-1 (or other available form) within 30 days of the Asset Purchase Agreement closing for the resale of shares issued to Erigen.
• Issuer to use reasonable best efforts to have the S-1 registration statement declared effective promptly and keep it continuously effective.
• Issuer to seek approval from stockholders for the issuance of shares upon exercise of warrants within 90 days following the date of the Purchase Agreement.
• Issuer to file registration statements under the Securities Act for the resale of common stock issued in the Private Placement and underlying warrants no later than 15 calendar days following the date of the Purchase Agreement.
• Issuer to use reasonable best efforts to have the Private Placement registration statement declared effective by 45 calendar days (or 75 days in case of full SEC review) following the date of the Purchase Agreement.

Key Dates

Recommendation

The substantial increase in CEO Matthew Angel's beneficial ownership to 37.4% is a strong positive signal, indicating high confidence in Tempest Therapeutics' future. The strategic asset acquisition and concurrent private placement provide capital and potentially expand the company's pipeline. However, the potential for future dilution from warrant exercises and the need for stockholder approval for warrant share issuance introduce some uncertainty. A 'hold' recommendation allows investors to monitor the company's execution on its strategic initiatives, progress on asset integration, and any clinical developments before making a more aggressive investment decision.

Keywords

Tempest Therapeutics, Matthew Angel, Schedule 13D, Insider Ownership, Beneficial Ownership, Asset Purchase Agreement, Securities Purchase Agreement, Private Placement, Warrants, Common Stock, Biotechnology, Corporate Governance